ABK Biomedical Completes Enrollment in ROUTE90 Pivotal Study for Primary Liver Cancer
PR Newswire —
Final Patient Treated in FDA IDE Study Evaluating Eye90 microspheres® for the Treatment of Unresectable Hepatocellular Carcinoma (HCC) HALIFAX, NS, Feb. 24, 2026 /PRNewswire/ - ABK Biomedical, Inc., an innovative, medical device company dedicated to the research, development, and...